$COHN

Cohen & Company Sets Release Date for Second Quarter 2025 Financial Results - Cohen & Co (AMEX:COHN)

PHILADELPHIA and NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Cohen & Company Inc. COHN will release its financial results for the second quarter 2025 on Thursday, July 31, 2025. The Company will host a conference call at 10:00 a.m. Eastern Time ( ET ) that day to discuss these results.

Original reporting
Benzinga · Globe Newswire
Published Jul 28, 2025, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cohen & Company Sets Release Date for Second Quarter 2025 Financial Results - Cohen & Co (AMEX:COHN) — source image
Decision brief

The 30-second read

$COHNNeutralMed
01

Why it matters

The scheduled release could lead to increased trading volume and volatility around July 31, 2025, depending on the results and market expectations.

02

Market read

The event is primarily relevant to traders and investors holding or considering positions in COHN, with limited broader market impact.

03

What to watch

Market-wide macroeconomic conditions or sector trends could overshadow company-specific news, affecting stock performance regardless of earnings.

Timing: high

Background

Cohen & Company Inc. is a financial services firm scheduled to announce its Q2 2025 financial results, which can influence short-term trading activity.

Company-level read

Ticker impact

$COHNNeutralMedium confidence
Context

The upcoming financial results release is a scheduled event that can influence short-term trading activity.

Expected impact

Potential for increased volatility; possible short-term upward or downward movement depending on results and market expectations.

Evidence & confidence

Scheduled earnings releases typically influence stock price volatility; however, without prior earnings data or analyst expectations, the direction is uncertain.

Market effects

Limited sector impact; the release pertains specifically to Cohen & Company Inc., a financial services firm, with no immediate sector-wide implications.

Minimal regional impact; the event is company-specific and scheduled in the U.S. markets.

Negligible global relevance; primarily of interest to investors and traders focused on the company's stock.

Counterpoint

The earnings release may be a non-event if results meet market expectations, leading to minimal price movement.

Key entities

  • Cohen & Company Inc.

    A financial services firm listed on the AMEX.

Related articles

$COHNMed

Cohen & Co Inc. (COHN): Results of Operations and Financial Condition

Cohen & Co Inc. (COHN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 COHEN & COMPANY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Board Declares Quarterly Dividend of $0.25 per Share Revenue of $69.5 Million Net Income Attributable to Cohen & Company Inc. of $3.6 Million, or $0.94 per Diluted Share Adjusted Pre-Tax Income of $10.1 Mi

$CMIIMedAI 8/10

2026 - 06 - 26 | Elroy Air to Become Publicly Traded Company via Business Combination with Inflection Point - led SPAC | NDAQ: CMII

Elroy Air will become a publicly traded company through a business combination with SPAC Columbus Circle Capital Corp II (Nasdaq: CMII), led by Inflection Point Asset Management. The deal values Elroy Air at about $800M pre-money and ~$1.0B enterprise value, with $165M+ committed PIPE capital. Closing is expected in Q4 2026. Elroy’s Chaparral VTOL drone targets 500+ lbs cargo; demand pipeline exceeds 1,400 aircraft and $5B potential revenue.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.